


NEWS RELEASE

DELMEICA INVESTMENTS January 3rd 2007



Delmedica offers the private equity investor access to unique biotechnology opportunities that have the hallmarks of commercially successful ventures.



MUCOAD™ UK PATENT Imminent

Delmedica Investments Limited ('DMI') has a concerted interest in Mucoad™ mucoadhesive compositions as a result of the Strategic Investment Agreement signed with Fortune Apex in October 2006.

DMI has today announced that the UK Patent for Mucoad™ mucoadhesive compositions is likely to be issued early in the New Year. The Patent Attorneys for Fortune Apex Development Limited ('Fortune Apex') have received communication from the UK Patent Office advising that the Patent could be granted as early as January 2007.

The Intellectual Property (patents /trademark filings) of Fortune Apex has undergone extensive Due Diligence by a specialist US legal team as required in forming a Joint Venture Company and as a pre-requisite to commercial licensing arrangements. Fortune Apex will receive a written opinion confirming that all criteria has been satisfied before year end.

Once granted, the UK Patent will protect the unique Mucoad™ mucoadhesive technology by providing a significant barrier to entry for competitors seeking to offer similar mucoadhesive systems.

The Mucoad™ trademark has been successfully registered in Australia, Japan and the UK and progress continues towards securing other key jurisdictions including the United States and EU. Detailed updates may be obtained by following the links as outlined below.

Patents

United Kingdom

UK Patent Application which was published under number **GB2423711**.

Visit

www.patent.gov.uk/tm/t-journal and enter the above publication number.

Trademarks

Australia

TM Registration No. **1095239**

Status. Registered until 2016 (access to Australian Patent Office Records available from www.ipaustralia.gov.au and downloading appropriate software).

European Community

TM Registration No. **004780722**

Status. Opposed 4/9/6. The opposition is minor and will be satisfied early in the New Year.

Follow via the OHIM web site by entering the TM Application number at <http://oami.europa.eu/CTMOnline>.

Japan

TM Registration No. **2006-4773**

Status. Registration Granted until 2016.

View: www3.ipdl.ncipi.go by entering the name Mucoad and 'searching'.

UK

TM Registration No. **GB2408938**

Status. Registered until December 2015.

Review the registration details by entering the registration number at www.patent.gov.uk/t-find-number and clicking 'view details'.

US

TM Registration No. **78787040**

Status. Awaiting examination.

You can check the status at <http://tarr.uspto.gov/> by entering the application number and clicking search.

Via the Joint Venture Company 'Strategic Pharmaceuticals Company LLC' ('SPC') (www.rxbiosci.com) Fortune Apex continues negotiations with a number of prominent American Pharmaceutical Corporations. It is anticipated the first license agreements for the MUCOAD™ technology will be signed in the first quarter of next year.

Early in 2007 the board of Fortune Apex will commission an independent valuation of the company and its patented technology to complement the Audited accounts. This valuation will be further enhanced by specialist analysis of the company and substantial commercial license agreements being signed.

The DMI Board is currently seeking advice regarding listing on one of the recognised stock exchanges I.e. 'GEM' and 'AIM' and accordingly, the company will continue to develop its existing technologies, acquire additional technologies and make further strategic investments.